Kutz et al. used a validated peptide platform for plasma determinations and observed in patients with COVID-19 lower levels of ANGI, ANGII, Ang1–5, and Ang1–7, and no changes in plasma ACE and ACE2 activities compared with a hospitalized patient group without COVID-19. Here, ACE2 is linked to COVID-19.